Steven Seedhouse
Stock Analyst at Raymond James
(3.46)
# 1,042
Out of 4,413 analysts
133
Total ratings
41.06%
Success rate
5.81%
Average return
Main Sectors:
Top Industries:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Outperform | $34 → $51 | $22.53 | +126.36% | 2 | Apr 18, 2024 | |
| VKTX Viking Therapeutics | Maintains: Outperform | $37 → $115 | $76.43 | +50.46% | 12 | Feb 27, 2024 | |
| VERA Vera Therapeutics | Upgrades: Strong Buy | $29 → $37 | $42.32 | -12.57% | 2 | Jan 26, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $46.05 | +130.18% | 14 | Jan 11, 2024 | |
| ARDX Ardelyx | Maintains: Strong Buy | $12 → $15 | $6.61 | +126.93% | 2 | Jan 9, 2024 | |
| DYN Dyne Therapeutics | Maintains: Strong Buy | $27 → $56 | $25.83 | +116.80% | 4 | Jan 4, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $78 → $64 | $25.72 | +148.83% | 15 | Dec 19, 2023 | |
| LPTX Leap Therapeutics | Maintains: Outperform | $19 → $18 | $3.27 | +435.17% | 8 | Nov 14, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $78 → $57 | $22.50 | +153.33% | 7 | Nov 10, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $5 → $4 | $2.00 | +100.00% | 5 | Nov 8, 2023 | |
| IFRX InflaRx | Maintains: Strong Buy | $21 → $19 | $1.41 | +1,247.52% | 9 | Nov 2, 2023 | |
| ZURA Zura Bio | Maintains: Strong Buy | $20 → $22 | $4.15 | +430.12% | 2 | Aug 15, 2023 | |
| WVE Wave Life Sciences | Initiates: Outperform | $7 | $5.67 | +23.46% | 1 | Jul 5, 2023 | |
| EDIT Editas Medicine | Upgrades: Outperform | $17 | $5.47 | +210.79% | 3 | Jun 13, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $33 → $35 | $22.53 | +55.35% | 4 | May 5, 2023 | |
| KYMR Kymera Therapeutics | Upgrades: Outperform | $38 | $36.24 | +4.86% | 2 | May 5, 2023 | |
| VBIV VBI Vaccines | Maintains: Outperform | $60 → $6 | $0.57 | +953.56% | 4 | Apr 13, 2023 | |
| ETNB 89bio | Maintains: Strong Buy | $25 → $50 | $8.75 | +471.43% | 7 | Mar 23, 2023 | |
| RNA Avidity Biosciences | Maintains: Strong Buy | $30 → $71 | $25.80 | +175.19% | 4 | Dec 15, 2022 | |
| GOSS Gossamer Bio | Maintains: Outperform | $15 → $5 | $0.71 | +606.71% | 5 | Dec 7, 2022 | |
| NEXI NexImmune | Downgrades: Market Perform | n/a | $3.18 | - | 4 | Nov 15, 2022 | |
| ANAB AnaptysBio | Maintains: Outperform | $30 → $38 | $26.02 | +46.04% | 2 | Nov 9, 2022 | |
| LABP Landos Biopharma | Downgrades: Market Perform | n/a | $22.29 | - | 4 | Aug 12, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Underperform | n/a | $27.91 | - | 4 | Aug 10, 2022 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Market Perform | n/a | $0.39 | - | 2 | May 18, 2022 | |
| GILD Gilead Sciences | Downgrades: Sell | n/a | $65.51 | - | 3 | May 1, 2020 | |
| BIIB Biogen | Downgrades: Sell | n/a | $216.13 | - | 2 | Apr 23, 2020 |
Dianthus Therapeutics
Apr 18, 2024
Maintains: Outperform
Price Target: $34 → $51
Current: $22.53
Upside: +126.36%
Viking Therapeutics
Feb 27, 2024
Maintains: Outperform
Price Target: $37 → $115
Current: $76.43
Upside: +50.46%
Vera Therapeutics
Jan 26, 2024
Upgrades: Strong Buy
Price Target: $29 → $37
Current: $42.32
Upside: -12.57%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $46.05
Upside: +130.18%
Ardelyx
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $6.61
Upside: +126.93%
Dyne Therapeutics
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $25.83
Upside: +116.80%
Mirum Pharmaceuticals
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $25.72
Upside: +148.83%
Leap Therapeutics
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $3.27
Upside: +435.17%
Intellia Therapeutics
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $22.50
Upside: +153.33%
ProQR Therapeutics
Nov 8, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $2.00
Upside: +100.00%
InflaRx
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $1.41
Upside: +1,247.52%
Zura Bio
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $4.15
Upside: +430.12%
Wave Life Sciences
Jul 5, 2023
Initiates: Outperform
Price Target: $7
Current: $5.67
Upside: +23.46%
Editas Medicine
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $5.47
Upside: +210.79%
Rocket Pharmaceuticals
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $22.53
Upside: +55.35%
Kymera Therapeutics
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $36.24
Upside: +4.86%
VBI Vaccines
Apr 13, 2023
Maintains: Outperform
Price Target: $60 → $6
Current: $0.57
Upside: +953.56%
89bio
Mar 23, 2023
Maintains: Strong Buy
Price Target: $25 → $50
Current: $8.75
Upside: +471.43%
Avidity Biosciences
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $25.80
Upside: +175.19%
Gossamer Bio
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.71
Upside: +606.71%
NexImmune
Nov 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.18
Upside: -
AnaptysBio
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $26.02
Upside: +46.04%
Landos Biopharma
Aug 12, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $22.29
Upside: -
Arcturus Therapeutics Holdings
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $27.91
Upside: -
Galmed Pharmaceuticals
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.39
Upside: -
Gilead Sciences
May 1, 2020
Downgrades: Sell
Price Target: n/a
Current: $65.51
Upside: -
Biogen
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $216.13
Upside: -